BrainsWay shared its Q3 2026 results, showing a 34% rise in sales to $18.1 million.

Nov 10, 2026, 9:22 AM ETResultsRead the original at Benzinga

Good for BWAY

BrainsWay's Q3 sales rose 34% to $18.1 million, and management expects full-year results near the top of its forecast range. The 12-patient Alzheimer’s study and uses not cleared by the FDA are cautions, but sales growth and recurring contracts support a stronger outlook.

BWAY · BrainsWay

AI read · Good for BWAY

The AI's read

More system shipments and long-term customer agreements give BrainsWay added sales opportunities and make future income more visible. The company also said it remains profitable. Some clinical findings remain early: the Alzheimer’s pilot involved 12 patients, and Deep TMS is not cleared for suicidal ideation or Alzheimer’s disease. Those limits temper the treatment story, but they do not erase the reported sales and contract growth.

Get alerts for BWAY

Follow BrainsWay (BWAY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BWAY

Free on the App Store and Google Play, or on the web.